Teva Pharmaceutical Industries (NYSE:TEVA) Earns Peer Perform Rating from Analysts at Wolfe Research

Wolfe Research started coverage on shares of Teva Pharmaceutical Industries (NYSE:TEVA) in a research note published on Friday, Briefing.com Automated Import reports. The brokerage issued a peer perform rating on the stock.

Several other equities analysts have also recently issued reports on the company. Maxim Group restated a hold rating on shares of Arlington Asset Investment in a research note on Thursday, May 2nd. Wells Fargo & Co set a $17.00 price objective on Teva Pharmaceutical Industries and gave the stock a hold rating in a research note on Tuesday, May 28th. Barclays restated a hold rating on shares of Bank of Montreal in a research note on Tuesday, June 11th. Credit Suisse Group began coverage on LTC Properties in a research note on Wednesday, July 10th. They set an underperform rating and a $19.00 price objective on the stock. Finally, Sanford C. Bernstein set a €108.00 ($125.58) price objective on Merck KGaA and gave the stock a neutral rating in a research note on Tuesday, June 18th. Six research analysts have rated the stock with a sell rating, fourteen have issued a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. Teva Pharmaceutical Industries currently has a consensus rating of Hold and a consensus target price of $15.39.

TEVA stock opened at $7.91 on Friday. Teva Pharmaceutical Industries has a twelve month low of $7.66 and a twelve month high of $25.96. The company has a debt-to-equity ratio of 1.66, a current ratio of 0.96 and a quick ratio of 0.62. The firm has a market capitalization of $8.04 billion, a P/E ratio of 2.83, a P/E/G ratio of 0.95 and a beta of 1.62. The stock’s 50 day moving average is $8.87.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings results on Thursday, May 2nd. The company reported $0.57 earnings per share for the quarter, topping analysts’ consensus estimates of $0.55 by $0.02. Teva Pharmaceutical Industries had a negative net margin of 18.66% and a positive return on equity of 16.84%. The business had revenue of $4.30 billion during the quarter, compared to the consensus estimate of $4.38 billion. During the same quarter last year, the company earned $0.94 earnings per share. The business’s quarterly revenue was down 15.2% compared to the same quarter last year. On average, research analysts forecast that Teva Pharmaceutical Industries will post 2.27 EPS for the current fiscal year.

In related news, Director Sol J. Barer acquired 111,000 shares of the business’s stock in a transaction that occurred on Monday, June 3rd. The shares were acquired at an average cost of $8.98 per share, for a total transaction of $996,780.00. Following the completion of the purchase, the director now directly owns 115,942 shares in the company, valued at $1,041,159.16. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, VP Notaristefani Carlo De sold 16,070 shares of Teva Pharmaceutical Industries stock in a transaction dated Monday, May 20th. The shares were sold at an average price of $11.42, for a total transaction of $183,519.40. Following the sale, the vice president now owns 49,659 shares in the company, valued at $567,105.78. The disclosure for this sale can be found here. 0.49% of the stock is owned by insiders.

A number of large investors have recently added to or reduced their stakes in TEVA. G&S Capital LLC grew its holdings in Teva Pharmaceutical Industries by 99.4% during the second quarter. G&S Capital LLC now owns 4,012 shares of the company’s stock worth $37,000 after acquiring an additional 2,000 shares during the period. Lindbrook Capital LLC increased its stake in Teva Pharmaceutical Industries by 61.2% in the 1st quarter. Lindbrook Capital LLC now owns 2,489 shares of the company’s stock worth $39,000 after purchasing an additional 945 shares in the last quarter. NEXT Financial Group Inc increased its stake in Teva Pharmaceutical Industries by 384.8% in the 2nd quarter. NEXT Financial Group Inc now owns 4,276 shares of the company’s stock worth $39,000 after purchasing an additional 3,394 shares in the last quarter. Cullen Frost Bankers Inc. purchased a new position in Teva Pharmaceutical Industries in the 1st quarter worth about $40,000. Finally, Edgemoor Investment Advisors Inc. purchased a new position in Teva Pharmaceutical Industries in the 1st quarter worth about $54,000. 65.05% of the stock is currently owned by hedge funds and other institutional investors.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

Recommended Story: What is a portfolio manager?

Analyst Recommendations for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.